Skip to search formSkip to main contentSkip to account menu

MK 0677

Known as: MK 677, MK-0677, MK-677 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ibutamoren mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults
Context The age-related decline of growth hormone secretion may play a role in sarcopenia and frailty. Content In this randomized… 
Highly Cited
2005
Highly Cited
2005
Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.
Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in… 
Highly Cited
2004
Highly Cited
2004
The Effects of MK‐0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture
Objectives: To evaluate the effects of MK‐0677, an orally active growth hormone (GH) secretagogue, on functional recovery from… 
Highly Cited
2001
Highly Cited
2001
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
GH increases bone turnover and stimulates osteoblast activity. We hypothesized that administration of MK-677, an orally active GH… 
Highly Cited
1998
Highly Cited
1998
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The… 
Highly Cited
1998
Highly Cited
1998
Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues.
1998
1998
Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males
The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK‐677 on markers of bone metabolism was… 
Highly Cited
1997
Highly Cited
1997
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
To determine the effect of the GH releasing peptide (GHRP)-mimetic, MK-677, on the GH/insulin-like growth factor-I (IGF-I) axis… 
Highly Cited
1997
Highly Cited
1997
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Previous studies have indicated the existence of common mechanisms regulating sleep and somatotropic activity. In the present… 
1996
1996
MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
MK-0677, a spiroindoline sulfonamide, is a novel, orally active GH secretagogue. The effects of MK-0677 on serum GH and other… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)